Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The submucosal tissue at the ureterovesical junction refers to the connective tissue layer found beneath the urothelial lining (mucosa) at the junction where the ureter inserts into the urinary bladder (the ureterovesical or vesicoureteric junction, UVJ/VUJ). This anatomical zone includes connective tissue and small vessels that support both the mucosal surface and the complex muscle layers involved in the "valve" mechanism that prevents the backflow (reflux) of urine. This structure is not a druggable protein, enzyme, or receptor, but defects or diseases involving this tissue (such as scarring, fibrosis, or developmental anomalies) can play a significant role in urological conditions such as vesicoureteral reflux and junctional obstruction, contributing to infections and possible kidney damage[1][2][3][4][6]. There are currently no direct drugs or biomarkers targeting the submucosal tissue of the UVJ, and references to this structure are strictly anatomical rather than molecular or pharmacological in nature.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Submucosal tissue at the ureterovesical junction.